Array BioPharma announced results from its Phase 2 study conducted by AstraZeneca of selumetinib (AZD6244/ARRY-886) in combination with docetaxel for the second-line treatment of KRAS-mutant, locally advanced or metastatic non-small cell lung cancer (NSCLC). The study’s primary endpoint of overall survival demonstrated a numerically greater increase in survival in favor of selumetinib in combination with docetaxel vs. docetaxel alone, but did not reach statistical significance. The key secondary endpoints of progression-free survival, objective response rate, and alive and progression-free at 6 months were all demonstrated with statistical significance, showing improvement in favor of selumetinib in combination with docetaxel vs. docetaxel alone.
Selumetinib is an anti-cancer drug in Phase 2 development in a range of tumors. It is a small molecule MEK inhibitor that targets a key position in the Ras-Raf-MEK-ERK signaling pathway. MEK has been shown to be frequently activated in cancer, in particular in tumors that have mutations in the RAS and RAF pathways.
For more information call (877) MED-CHEM or visit http://www.arraybiopharma.com.